Regulation of cognition and symptoms of psychosis: Focus on GABAA receptors and glycine transporter 1`

Pharmacology Biochemistry and Behavior

Volumn 90, Issue 1, 2008, Pages 58-64

  Möhler, Hanns ^a   Rudolph, Uwe ^b   Boison, Detlev ^c   Singer, Philipp ^d   Feldon, Joram ^d   Yee, Benjamin K ^d  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b MCLEAN HOSPITAL   (United States)

^c LEGACY RESEARCH   (United States)

^d ETH ZURICH   (Switzerland)

Author keywords

Anxiety; Cognition; GABAA receptors; Glycine transporter 1; Memory and learning; Pychosis

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 7 TERT BUTYL 3 (2,5 DIFLUOROPHENYL) 6 (2 METHYL 2H 1,2,4 TRIAZOL 3 YLMETHOXY) 1,2,4 TRIAZOLO[4,3 B]PYRIDAZINE; AMPHETAMINE; CYCLOSERINE; DIAZEPAM; GLYCINE TRANSPORTER 1; HALOPERIDOL; KETAMINE; MUSCIMOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PENTOBARBITAL; PHENCYCLIDINE; SARCOSINE; TP 003; TPA 023; ZOLPIDEM;

ASSOCIATIVE MEMORY; BEHAVIOR; COGNITION; DRUG BINDING SITE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIVITY; DRUG TARGETING; EXCITABILITY; FOREBRAIN; GENETIC MANIPULATION; HIPPOCAMPUS; LATENT INHIBITION; NERVE CELL; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PSYCHOSIS; RECOGNITION; REVIEW; SCHIZOPHRENIA; SEDATION; SELECTIVE ATTENTION; SENSORIMOTOR FUNCTION; STATE DEPENDENT LEARNING; TRANQUILIZING ACTIVITY; WORKING MEMORY;

ANIMALS; ANTI-ANXIETY AGENTS; ASSOCIATION LEARNING; BEHAVIOR; BEHAVIOR, ANIMAL; COGNITION; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; HYPNOTICS AND SEDATIVES; MEMORY; PSYCHOTIC DISORDERS; RECEPTORS, GABA-A;

MUS;

EID: 44649151000     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2008.03.003     Document Type: Review

References (97)

1. Akirav I. NMDA partial agonist reverses blocking of extinction of aversive memory by GABA(A) agonist in the amygdala. Neuropsychopharmacology 32 (2007) 542-550
2. A receptors, is a nonsedating anxiolytic in rodents and primates. J Pharmacol Exp Ther 316 (2006) 410-422
3. A receptor subtype selectivity to abuse liability and dependence potential of pharmacological treatments for anxiety and sleep disorders. CNS Spectr 10 (2005) 31-39
4. Baruch I., Hemsley D.R., and Gray J.A. Differential performance of acute and chronic schizophrenics in a latent inhibition task. J Nerv Ment Dis 176 (1988) 598-606
5. Bast T., and Feldon J. Hippocampal modulation of sensorimotor processes. Prog Neurobiol 70 (2003) 319-345
6. Benes M.F., Lim B., Matzilevich D., Walsh J.P., Subburaju S., and Minns M. Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars. Proc Natl Acad Sci U S A 104 (2007) 10164-10169
7. Bergeron R., Meyer T.M., Coyle J.T., and Greene R.W. Modulation of N-methyl-d-aspartate receptor function by glycine transport. Proc Natl Acad Sci U S A 95 (1998) 15730-15734
8. 5 subunit-containing γ-aminobutyric acid type A receptors. Proc Natl Acad Sci U S A 101 (2004) 3662-3667
9. A alpha5 receptors with cognition enhancing properties. J Med Chem 47 (2004) 5829-5832
10. A receptor. J Neurosci 22 (2002) 5572-5580
11. A receptors improves encoding and recall but not consolidation in the Morris water maze. Psychopharmacology 88 (2006) 619-628
12. Coyle J.T. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 26 (2006) 365-384
13. Coyle J.T., and Tsai G. NMDA receptor function, neuroplasticity, and the pathophysiology of schizophrenia. Int Rev Neurobiol 59 (2004) 491-515
14. Crestani F., Martin J.R., Möhler H., and Rudolph U. Mechanism of action of the hypnotic zolpidem in vivo. Br J Pharmacol 131 (2000) 1251-1254
15. Crestani F., Keist R., Fritschy J.M., Benke D., Vogt K., Prut L., et al. Trace fear conditioning involves hippocampal alpha5 GABA(A) receptors. Proc Natl Acad Sci U S A 99 (2002) 8980-8985
16. Davis M., and Myers K.M. The role of glutamate and gamma-aminobutyric acid in fear extinction: clinical implications for exposure therapy. Biol Psychiatry 52 (2002) 998-1007
17. Davis S., Butcher S.P., and Morris R.G.M. The NMDA receptor antagonist d-2-amino-5-phosphonopentanoate (d-AP5) impairs spatial learning and LTP in vivo at intracerebral concentrations comparable to those that block LTP in vitro. J Neurosci 12 (1992) 21-34
18. Depoortère R., Dargazanli G., Estenne-Bouhtou G., Coste A., Lanneau C., Desvignes C., et al. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology 30 (2005) 1963-1985
19. Depoortere R., Dargazanli G., Estenne-Bouhtou G., Coste A., Lanneau C., Desvignes C., et al. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology 30 (2005) 1963-1985
20. A receptors in mediating the anxiolytic effects of benzodiazepines. J Neurosci 25 (2005) 10682-10688
21. Farber N.B. The NMDA receptor hypofunction model of psychosis. Ann NY Acad Sci 1003 (2003) 119-130
22. A receptor heterogeneity in the adult rat brain: differential regional and cellular distribution of seven major subunits. J Comp Neurol 359 (1995) 154-194
23. Fritschy J.M., Weinmann O., Wenzel A., and Benke D. Synapse-specific localization of NMDA and GABA(A) receptor subunits revealed by antigen-retrieval immunohistochemistry. J Comp Neurol 390 (1998) 194-210
24. Fritschy J.M., Johnson D.K., Möhler H., and Rudolph U. Independent assembly and subcellular targeting of GABA(A)-receptor subtypes demonstrated in mouse hippocampal and olfactory neurons in vivo. Neurosci Lett 249 (1998) 99-102
25. Gerdjikov T.V., Rudolph U., Keist R., Möhler H., Feldon J., and Yee B.K. Hippocampal alpha5 subunit-containing GABA(A) receptors are involved in the development of the latent inhibition effect. Neurobiol Learn Mem 89 (2008) 87-94
26. 5 subunit-deficient mice. J Neurophysiol 95 (2006) 2796-2807
27. Goff D.C., and Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158 (2001) 1367-1377
28. Gray J.A., and Roth B.L. The pipeline and future of drug development in schizophrenia. Mol Psychiatry 12 (2007) 904-922
29. Gray J.A., Feldon J., Rawlins J.N.P., Hemsley D.R., and Smith A.D. The neuropsychology of schizophrenia. Behav Brain Res 14 (1991) 1-84
30. Gray J.A., Joseph M.H., and Hemsley D.R. The role of mesolimbic dopaminergic and retrohippocampal afferents to the nucleus accumbens in latent inhibition: implications for schizophrenia. Behav Brain Res 71 (1996) 19-31
31. Gray N.S., Hemsley D.R., and Gray J.A. Abolition of latent inhibition in acute, but not chronic schizophrenics. Neurol Psychiatry Brain Res 1 (1992) 83-89
32. Harsing Jr. L.G., Gacsalyi I., Szabo G., Schmidt E., Sziray N., Sebban C., et al. The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study. Pharmacol Biochem Behav 74 (2003) 811-825
33. Harsing Jr. L.G., Juranyi Z., Gacsalyi I., Topalcsanyi P., Czompa A., and Matyus P. Glycine transporter type-1 and its inhibitors. Curr Med Chem 13 (2006) 1017-1044
34. A receptors modulate expression of prepulse inhibition. Mol Psychiatry 10 (2005) 201-207
35. Heresco-Levy U. Adding sarcosine, but not d-serine, to risperidone improves symptoms in people with acute phase schizophrenia. Evid-Based Ment Health 9 (2006) 48
36. Huerta P.T., Sun L.D., Wildon M.A., and Tonegawa S. Formation of temporal memory requires NMDA receptors within CA1 pyramidal neurons. Neuron 24 (2000) 473-480
37. Igartua I., Solís J.M., and Bustamante J. Glycine-induced long-term synaptic potentiation is mediated by the glycine transporter GlyT1. Neuropharmacology 52 (2007) 1586-1595
38. Javitt D.C. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 9 (2004) 984-997
39. Johnson J.W., and Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 325 (1987) 529-531
40. Kraemer P.J., and Spear N.E. The effect of nonreinforced stimulus exposure on the strength of a conditioned taste aversion as a function of retention interval: do intent inhibition and extinction involve a shared process. Anim Learn Behav 20 (1991) 1-7
41. Kraemer P.J., and Spear N.E. Retrieval processes and conditioning. In: Zentall T.R. (Ed). Animal cognition. A tribute to Donald A. Riley (1993), Lawrence Erlbaum, New Jersey 87-110
42. Lane H.Y., Chang Y.C., Liu Y.C., Chiu C.C., and Tsai G.E. Sarcosine or d-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry 62 (2005) 1196-1204
43. Lechner S.M. Glutamate-based therapeutic approaches: inhibitors of glycine transport. Curr Opin Pharmacol 6 (2006) 75-81
44. Lewis D.A., Hashimoto T., and Volk D.W. Cortical inhibitory neurons and schizophrenia. Nature Rev Neurosci 6 (2005) 312-324
45. Lindsley C.W., Wolkenberg S.E., and Kinney G.G. Progress in the preparation and testing of Glycine transporter type-1 (GlyT1) inhibitors. Curr Top Med Chem 6 (2006) 1883-1896
46. Lipska B.K., and Weinberger D.R. A neurodevelopmental model of schizophrenia: neonatal disconnection of the hippocampus. Neurotox Res 4 (2002) 469-475
47. Löw K., Crestani F., Keist R., Benke D., Benson J.A., Brunig I., et al. Molecular and neuronal substrate for the selective attenuation of anxiety. Science 290 (2000) 131-134
48. Lubow R.E. Latent inhibition and conditioned attentional theory (1989), Cambridge University Press, Cambridge, UK
49. Lubow R.E., and Moore A.U. Latent inhibition: the effect of nonreinforced pre-exposure to the conditional stimulus. J Comp Physiol Psychol 52 (1959) 415-419
50. Mackintosh N.J. Stimulus selection: learning to ignore stimuli that predict no change in reinforcement. In: Hinde R.A., and Stevenson-Hinde J. (Eds). Constraints on learning (1973), Academic Press, London 75-96
51. Mackintosh N.J. The psychology of animal learning (1974), Academic Press, London
52. Mackintosh N.J. A theory of attention: variations in the associability of stimuli with reinforcement. Psychol Rev 82 (1975) 276-298
53. McHugh T.J., Blum K.I., Tsien J.Z., Tonegawa S., and Wilson M.A. Impaired hippocampal representation of space in CA1-specific NMDAR1 knockout mice. Cell 87 (1996) 1339-1349
54. 1 subtype. Nat Neurosci 3 (2000) 587-592
55. Meyer U., Feldon J., Schedlowski M., and Yee B.K. Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia. Neurosci Biobehav Rev 29 (2005) 913-947
56. Möhler H. Molecular regulation of cognitive functions and developmental plasticity: impact of GABA-A receptors. J Neurochem 102 (2007) 1-12
57. Möhler H. Functional relevance of GABA-A receptor subtypes. In: Enna S.J., and Möhler H. (Eds). The GABA receptors (2007), Humana Press 23-40
58. A circuits for novel CNS drugs. Drug Discovery Today 1 (2004) 117-123
59. Möhler H., Fritschy J.M., and Rudolph U. A new benzodiazepine pharmacology. J Pharmacol Exp Ther 300 (2002) 2-8
60. Morris R.G.M., Anderson A., Lynch G.S., and Baudry M. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-d-aspartate receptor antagonist AP5. Nature 319 (1986) 774-776
61. Myers K.M., and Davis M. Behavioral and neural analysis of extinction. Neuron 36 (2002) 567-584
62. Myers K.M., and Davis M. Mechanisms of fear extinction. Mol Psychiatry 12 (2007) 120-150
63. Nakazawa K., Quirk M.C., Chitwood R.A., Watanabe M., Yeckel M.F., Sun L.D., et al. Requirement for hippocampal CA3 NMDA receptors in associative memory recall. Science 297 (2002) 211-218
64. Nusser Z., Sieghart W., Benke D., Fritschy J.M., and Somogyi P. Differential synaptic localization of two major gamma-aminobutyric acid type A receptor alpha subunits on hippocampal pyramidal cells. Proc Natl Acad Sci U S A 93 (1996) 11939-11944
65. A receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. Neuroscience 101 (2000) 815-850
66. A receptors mediate phasic and tonic forms of inhibition in hippocampal pyramidal neurons. J Neurophysiol 2 (2006) 846-857
67. A receptor subtype functions. Curr Opin Pharmacol 6 (2006) 18-23
68. Rudolph U., Crestani F., Benke D., Brünig I., Benson J., Fritschy J.M., et al. Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes. Nature 401 (1999) 796-800
69. A receptor subtypes: dissecting their pharmacological functions. Trends Pharmacol Sci 22 (2001) 188-194
70. A receptor currents in the hippocampus. J Neurosci 25 (2005) 10016-10024
71. Sesack S.R., and Pickel V.M. In the rat medial nucleus accumbens, hippocampal and catecholaminergic terminals converge on spiny neurons and are in opposition to each other. Brain Res 527 (1990) 266-279
72. Singer P., Boison D., Möhler H., Feldon J., and Yee B.K. Enhanced recognition memory following glycine transporter 1 deletion in forebrain neurons. Behav Neurosci 221 (2007) 815-825
73. Smith K.E., Borden L.A., Hartig P.R., Branchek T., and Weinshank R.L. Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors. Neuron 8 (1992) 927-935
74. Somogyi P., and Klausberger T. Defined types of cortical interneurone structure space and spike timing in the hippocampus. J Physiol 562 (2005) 9-26
75. Spencer K.M., Nestor P.G., Perlmutter R., Niznikiewicz M.A., Klump M.C., Frumin M., et al. Neural synchrony indexes disordered perception and cognition in schizophrenia. Proc Natl Acad Sci U S A 101 (2004) 17288-17293
76. A receptor alpha3 subunit-null mice. Eur J Neurosci 24 (2006) 1307-1315
77. Supplisson S., and Bergman C. Control of NMDA receptor activation by a glycine transporter co-expressed in Xenopus oocytes. J Neurosci 17 (1997) 4580-4590
78. Sur C., and Kinney G.G. Glycine transporter 1 inhibitors and modulation of NMDA receptor-mediated excitatory neurotransmission. Curr Drug Targets 8 (2007) 643-649
79. Tang Y.P., Shimizu E., Dube G.R., Rampon C., Kerchner G.A., Zhou M., et al. Genetic enhancement of learning and memory in mice. Nature 401 (1999) 63-69
80. Totterdell S., and Smith A.D. Convergence of hippocampal and dopaminergic input onto identified neurons in the nucleus accumbens of the rat. J Chem Neuroanat 2 (1989) 285-298
81. Tsai G., and Coyle J.T. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 42 (2002) 165-179
82. Tsai G., Ralph-Williams R.J., Martina M., Bergeron R., Berger-Sweeney J., Dunham K.S., et al. Gene knockout of glycine transporter 1: characterization of the behavioral phenotype. Proc Natl Acad Sci U S A 101 (2004) 8485-8490
83. Tsai G., Lane H.Y., Yang P., Chong M.Y., and Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 55 (2004) 452-456
84. Tsien J.Z., Huerta P.T., and Tonegawa S. The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory. Cell 87 (1996) 1327-1338
85. Verdoorn T.A., Kleckner N.W., and Dingledine R. Rat brain N-methyl-d-aspartate receptors expressed in Xenopus oocytes. Science 238 (1987) 1114-1116
86. Waldvogel H.J., Baer K., Gai W.P., Gilbert R.T., Rees M.I., Möhler H., et al. Differential localisation of GABA-A receptor subunits within the substantia nigra of the human brain: an immunohistochemical study. J Comp Neurol 506 (2008) 912-929
87. Walter M.W., Hoffman B.J., and Gordon K. Discovery and SAR studies of novel GlyT1 inhibitors. Bioorg Med Chem Lett 17 (2007) 5233-5238
88. Weiner I. Neural substrates of latent inhibition: the switching model. Psychol Bull 108 (1990) 442-461
89. Weiner I., and Feldon J. The switching model of latent inhibition: an update of neural substrates. Behav Brain Res 88 (1997) 11-25
90. A receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Dev 6 (2003) 648-655
91. A receptor subtypes in the brain: a paradigm for CNS drug discovery?. Drug Discov Today 8 (2003) 445-450
92. A receptors based on subunit composition. In: Martin D.L., and Olsen R.W. (Eds). GABA in the nervous system: the view at fifty years (2000), Lippincott, Philadelphia 113-126
93. Whittington M.A., Faulkner H.J., Doheny H.C., and Traub R.D. Neuronal fast oscillations as a target site for psychoactive drugs. Pharmacol Ther 86 (2000) 171-190
94. Yee B.K., Feldon J., and Rawlins J.N.P. Latent inhibition in rats is abolished by NMDA-induced neuronal loss in the retrohippocampal region, but this lesion effect can be prevented by systemic haloperidol treatment. Behav Neurosci 109 (1995) 227-240
95. Yee B.K., Hauser J., Dolgov V.V., Keist R., Möhler H., Rudolph U., et al. GABA receptors containing the alpha5 subunit mediate the trace effect in aversive and appetitive conditioning and extinction of conditioned fear. Eur J Neurosci 20 (2004) 1928-1936
96. A receptors to a dopamine hyperfunction. Proc Natl Acad Sci U S A 102 (2005) 17154-17159
97. Yee B.K., Balic E., Singer P., Schwerdel C., Grampp T., Gabernet L., et al. Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile. J Neurosci 26 (2006) 3169-3181